Document is current
Any future updates will be listed below
-
Authors
Gulhati, Pat
Schalck, Aislyn
Jiang, Shan
Shang, Xiaoying
Wu, Chang-Jiun https://orcid.org/0000-0001-8350-6397
Hou, Pingping https://orcid.org/0000-0002-2429-0861
Ruiz, Sharia Hernandez
Soto, Luisa Solis https://orcid.org/0000-0002-1253-630X
Parra, Edwin https://orcid.org/0000-0001-9068-1636
Ying, Haoqiang https://orcid.org/0000-0003-0616-2310
Han, Jincheng
Dey, Prasenjit
Li, Jun
Deng, Pingna
Sei, Emi
Maeda, Dean Y. https://orcid.org/0000-0002-9304-6846
Zebala, John A.
Spring, Denise J. https://orcid.org/0000-0002-4593-0901
Kim, Michael
Wang, Huamin https://orcid.org/0000-0002-2038-5863
Maitra, Anirban https://orcid.org/0000-0001-7923-9978
Moore, Dirk
Clise-Dwyer, Karen
Wang, Y. Alan
Navin, Nicholas E. https://orcid.org/0000-0002-2106-8624
DePinho, Ronald A. https://orcid.org/0000-0002-5625-577X
- License Information
-
More Information
Article History
Received: 4 August 2022
Accepted: 18 November 2022
First Online: 30 December 2022
Competing interests
: R.A.D. is a founder, advisor and/or director of Tvardi Therapeutics, Asylia Therapeutics, Stellanova Therapeutics, Nirogy Therapeutics and Sporos Bioventures. J.A.Z. is the President and Chief Executive Officer at Syntrix Pharmaceuticals. D.Y.M. is the Director of Medicinal Chemistry and Preclinical Development at Syntrix Pharmaceuticals. A.M. receives royalties from Cosmos Wisdom Biotechnology and Thrive Earlier Detection, an Exact Sciences company. A.M. is also a consultant for Freenome and Tezcat Biotechnology. The other authors declare no competing interests.
